{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:36:08Z","timestamp":1792881368964,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Allogeneic hematopoietic cell transplantation is a potentially curative therapy for acute myeloid leukemia (AML), but its success is limited by graft-versus-host disease (GvHD). Optimal in vivo T-cell depletion strategies for GvHD prophylaxis given with conditioning regimens remain under investigation. We compared antithymocyte globulin (ATG) and alemtuzumab as GvHD prophylaxis in adult AML patients in complete remission (CR1\/CR2) undergoing allogeneic cell transplantation from unrelated-donors conditioned with intermediate-intensity regimens. From the EBMT registry, 1545 patients were identified (710 ATG; 835 alemtuzumab). Patients receiving ATG were slightly older and had higher comorbidity scores, but groups were otherwise comparable. At 3 years, ATG was associated with superior overall survival (58.3% vs. 50.4%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03) and leukemia-free survival (52.1% vs. 45.7%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.014). ATG recipients also demonstrated significantly lower relapse incidence (21.9% vs. 28.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006), while non-relapse mortality remained similar between groups (26% vs. 26.3%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.46). Although ATG was associated with a higher incidence of acute GvHD, chronic GvHD rates did not differ significantly. In summary, for AML patients in complete remission receiving intermediate-intensity conditioning, ATG improved long-term survival and reduced relapse risk compared with alemtuzumab, despite increased acute GvHD. These findings support ATG as an effective GvHD prophylactic option in this setting.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-03016-7","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:38:05Z","timestamp":1789036685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8287-5673","authenticated-orcid":false,"given":"Jes\u00fas","family":"Duque-Afonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1799-5927","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allain-Thibeault","family":"Ferhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8858-923X","authenticated-orcid":false,"given":"Deborah","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-5332","authenticated-orcid":false,"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tholouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Besley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3362-5814","authenticated-orcid":false,"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-0795","authenticated-orcid":false,"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6565-3393","authenticated-orcid":false,"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Bloor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Crawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Clesham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Medd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8090-0349","authenticated-orcid":false,"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3895","authenticated-orcid":false,"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-2253","authenticated-orcid":false,"given":"Eva Maria","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Gadisseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4471-418X","authenticated-orcid":false,"given":"Eolia","family":"Brissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"3016_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Atlija M, Kleovoulou I, Witaszek A, Alexander T, et al. The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT. Bone Marrow Transpl. 2025;60:519\u201328.","journal-title":"Bone Marrow Transpl"},{"key":"3016_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute Graft-versus-Host Disease\u2013Biologic Process, Prevention, and Therapy. N Engl J Med. 2017a;377:2167\u201379.","journal-title":"N Engl J Med"},{"key":"3016_CR3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017b;377:2565\u201379.","journal-title":"N Engl J Med"},{"key":"3016_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46989\/001c.124926","volume":"6","author":"R Shah","year":"2024","unstructured":"Shah R, Murphy D, Logue M, Jerkins J, Jallouk A, Adetola K, et al. Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease. Clin Hematol Int. 2024;6:74\u201388.","journal-title":"Clin Hematol Int"},{"key":"3016_CR5","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood. 2000;96:2419\u201325.","journal-title":"Blood"},{"key":"3016_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855\u201364.","journal-title":"Lancet Oncol"},{"key":"3016_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"3016_CR8","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.bbmt.2009.08.002","volume":"15","author":"H Bertz","year":"2009","unstructured":"Bertz H, Spyridonidis A, W\u00e4sch R, Gr\u00fcllich C, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of de-escalation. Biol Blood Marrow Transpl. 2009;15:1563\u201370.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3016_CR9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/bmt.2010.308","volume":"46","author":"A Spyridonidis","year":"2011","unstructured":"Spyridonidis A, Liga M, Triantafyllou E, Themeli M, Marangos M, Karakantza M, et al. Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. Bone Marrow Transpl. 2011;46:1363\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"3016_CR10","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2010-04-282392","volume":"116","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116:5824\u201331.","journal-title":"Blood"},{"key":"3016_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1399-3062.2009.00414.x","volume":"11","author":"SH Park","year":"2009","unstructured":"Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis. 2009;11:413\u201323.","journal-title":"Transpl Infect Dis"},{"key":"3016_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"19","author":"AM Raiola","year":"2013","unstructured":"Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transpl. 2013;19:117\u201322.","journal-title":"Biol Blood Marrow Transpl"},{"key":"3016_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/ejh.13085","volume":"101","author":"M Robin","year":"2018","unstructured":"Robin M, Raj K, Chevret S, Gauthier J, de Lavallade H, Michonneau D, et al. Alemtuzumab vs anti-thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. Eur J Haematol. 2018;101:466\u201374.","journal-title":"Eur J Haematol"},{"key":"3016_CR14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"F Baron","year":"2014","unstructured":"Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transpl. 2014;49:389\u201396.","journal-title":"Bone Marrow Transpl"},{"key":"3016_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/s41409-023-02095-0","volume":"58","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Kr\u00f6ger N, Schroeder T, Gedde-Dahl T, Eder M, et al. The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP \/EBMT. Bone Marrow Transpl. 2023;58:1339\u201347.","journal-title":"Bone Marrow Transpl"},{"key":"3016_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.94952","volume":"6","author":"J Sawyer","year":"2024","unstructured":"Sawyer J, Elliott T, Orton L, Sowell H, Gatwood K, Shultes K. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int. 2024;6:1\u201310.","journal-title":"Clin Hematol Int"},{"key":"3016_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"3016_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"3016_CR19","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610\u20131.","journal-title":"Bone Marrow Transpl"},{"key":"3016_CR20","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#","volume":"18","author":"PK Andersen","year":"1999","unstructured":"Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489\u2013500.","journal-title":"Stat Med"},{"key":"3016_CR21","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","volume":"126","author":"SO Ciurea","year":"2015","unstructured":"Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033\u201340.","journal-title":"Blood"},{"key":"3016_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","volume":"11","author":"A Ruggeri","year":"2018","unstructured":"Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40.","journal-title":"J Hematol Oncol"},{"key":"3016_CR23","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO-24-02477","volume":"43","author":"R Zeiser","year":"2025","unstructured":"Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, et al. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025;43:2566\u201371.","journal-title":"J Clin Oncol"},{"key":"3016_CR24","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1200\/JCO.22.00509","volume":"41","author":"DB Miklos","year":"2023","unstructured":"Miklos DB, Abu Zaid M, Cooney JP, Albring JC, Flowers M, Skarbnik AP, et al. Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study. J Clin Oncol. 2023;41:1876\u201387.","journal-title":"J Clin Oncol"},{"key":"3016_CR25","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-21-4176","volume":"28","author":"D Przepiorka","year":"2022","unstructured":"Przepiorka D, Le RQ, Ionan A, Li RJ, Wang YH, Gudi R, et al. FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy. Clin Cancer Res. 2022;28:2488\u201392.","journal-title":"Clin Cancer Res"},{"key":"3016_CR26","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2401537","volume":"391","author":"D Wolff","year":"2024","unstructured":"Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, et al. AGAVE-201 Investigators. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024;391:1002\u201314.","journal-title":"N Engl J Med"},{"key":"3016_CR27","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","volume":"11","author":"O Penack","year":"2024","unstructured":"Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:e147\u2013e159.","journal-title":"Lancet Haematol"},{"key":"3016_CR28","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1365-2141.2005.05513.x","volume":"129","author":"N Kr\u00f6ger","year":"2005","unstructured":"Kr\u00f6ger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, et al. Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol. 2005;129:631\u201343.","journal-title":"Br J Haematol"},{"key":"3016_CR29","doi-asserted-by":"crossref","unstructured":"Neumann T, Schneidewind L, Thiele T, Pink D, Schulze M, Schmidt C, et al. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation. Transpl Infect Dis. 2018;20.","DOI":"10.1111\/tid.12822"},{"key":"3016_CR30","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1200\/JCO.20.01086","volume":"39","author":"B Watkins","year":"2021","unstructured":"Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021;39:1865\u201377.","journal-title":"J Clin Oncol"},{"key":"3016_CR31","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1038\/s41591-024-03016-4","volume":"30","author":"YB Chen","year":"2024","unstructured":"Chen YB, Mohty M, Zeiser R, Teshima T, Jamy O, Maertens J, et al. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial. Nat Med. 2024;30:2277\u201387.","journal-title":"Nat Med"},{"key":"3016_CR32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1182\/blood-2025-932","volume":"146","author":"S Srour","year":"2025","unstructured":"Srour S, Abedi M, Salhotra A, Waller E, Choe H, Pavlova A, et al. Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies. ASH Meet. 2025;146:932. https:\/\/doi.org\/10.1182\/blood-2025-932.","journal-title":"ASH Meet"},{"key":"3016_CR33","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1182\/blood.2024028005","volume":"145","author":"Z DeFilipp","year":"2025","unstructured":"DeFilipp Z, Kim HT, Knight LW, O\u2019Connor SM, Dhaver SE, White M, et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood. 2025;145:2312\u20136.","journal-title":"Blood"},{"key":"3016_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41409-024-02459-0","volume":"60","author":"JR Passweg","year":"2025","unstructured":"Passweg JR, Baldomero H, Alexander T, Angelucci E, Averbuch D, Bazarbachi A, et al. Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT. Bone Marrow Transpl. 2025;60:227\u201336.","journal-title":"Bone Marrow Transpl"}],"updated-by":[{"DOI":"10.1038\/s41409-026-03073-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000}}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03016-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03016-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T22:02:27Z","timestamp":1792879347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03016-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":34,"alternative-id":["3016"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03016-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In this article the author name \u201cThibeault Ferhat-Berland\u201d should read \u201cAllain-Thibeault Ferhat\u201d.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41409-026-03073-y","URL":"https:\/\/doi.org\/10.1038\/s41409-026-03073-y","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests with the publication of this article. JD-A has received speaker\u2019s honoraria from Roche, Amgen, AstraZeneca, Beigene, Abbvie, Lilly, Janssen, Riemser, Ipsen, and Sobi and travel support from Alexion, Beigene, Gilead, and Sobi. JF has received research support and speaker\u2019s honoraria from Medac, Neovii, and Riemser. FS has received travel support from Neovii and Medac and research support from Medac and honoraria from Medac.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the general assembly of the ALWP of the EBMT. All methodology was performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Patient authorization was obtained via informed consent to include their data in the EBMT registry.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}